Fluidigm is collaborating with the Zhongshan, China-based company Ascendas Genomics to develop molecular diagnostics in China. Under the terms of the partnership, Ascendas Genomics will develop and commercialize molecular diagnostic systems and assays using microfluidic technologies included in the Fluidigm Biomark HD and Juno systems. Fluidigm’s microfluidic technology enables scalable and automated workflows for quantitative polymerase chain reaction, gene expression, copy number variation analysis, and next-generation sequencing library preparation. “The Juno and Biomark HD systems demonstrate superior performance in automation and ease of use, and provide great potential to advance diagnostic testing for the clinical labs and hospitals in China to enable the future of precision medicine,” said Chengyong Yang, PhD, chairman and CEO of Ascendas Genomics.